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Abstract
Objective. To determine the economic feasibility inAustralian general practices of using a practice nurse (PN)-led care
model of chronic disease management.
Methods. A cost-analysis of item numbers from the Medicare Benefit Schedule (MBS) was performed in three
Australian general practices, one urban, one regional and one rural. Patients (n =254; >18 years of age) with chronic
conditions (type 2 diabetes, hypertension, ischaemic heart disease) but without unstable or major health problems were
randomised into usual general practitioner (GP) or PN-led care formanagement of their condition over a period of 12months.
After the 12-month intervention, total MBS item charges were evaluated for patients managed for their stable chronic
condition by usual GP or PN-led care. Zero-skewness log transformation was applied to cost data and log-linear regression
analysis was undertaken.
Results. There was an estimated A$129 mean increase in total MBS item charges over a 1-year period (controlled for
age, self-reported quality of life and geographic location of practice) associated with PN-led care. The frequency of GP and
PN visits varied markedly according to the chronic disease.
Conclusions. Medicare reimbursements provided sufficient funding for general practices to employ PNs within limits
of workloads before the new Practice Nurse Incentive Program was introduced in July 2012.
What is known about the topic? The integration of practice nurses (PN) into the Australian health system is limited
compared with the UK and other parts of Europe. There are known patient benefits of PNs collaborating with general
practitioners, especially in chronic disease management, but the benefits from a financial perspective are less clear.
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What does this paper add? The cost-analysis of a PN-led model of chronic disease management in Australian general
practice is reported, providing an indication of the financial impact of using PNs in primary healthcare.
What are the implications for practitioners? Taking into account general practice and individual PN workloads,
sufficient funding for employment of PNs is provided by Medicare reimbursements.
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Introduction
Practice nurses (PN) are a valued part of primary health care
delivery in several health systems internationally. Their inte-
gration into the health systems in the UK and other parts of
Europe is well developed,1–3 but remains limited in Australia.
However, the Australian Government’s Practice Nurse Incen-
tive Program (PNIP), launched in 2012, is a recent initiative
aimed at scaling up the role of PNs within the primary health
setting.4
There are known benefits of PNs collaborating with general
practitioners (GPs),1,5–9 including high levels of patient satis-
faction, effective care coordination with GPs and enhanced
communication to assist patients to take greater responsibility
in managing chronic diseases.5–7 However, from a financial
perspective, the benefits of PNs for general practices are less
clear. In the UK, costs of substituting cheaper PN consultations
instead of sessions with a GP are offset by PNs having longer
consultations, carrying out more tests and requesting more
follow-up visits.8,9 Medicare Australia introduced payments for
services undertaken by a PN on behalf of a medical practitioner,
such as payment for PNs to undertake chronic disease manage-
ment on 1 November 2007.10 In 2012, when the PNIP was
introduced, many of these Medicare Benefit Schedule (MBS)
item numbers were replaced by block funding for nursing
services. However, the item number for chronic disease man-
agement remains.
The financial impact of using PNs in primary healthcare has
not been analysed previously within the Australian Medicare
system. This article presents an economic feasibility analysis for
a PN-led model of chronic disease management in Australian
general practice.5,11 We develop a business case based on the
total MBS item charges for patients who were managed for their
stable chronic disease by usual GP- or PN-led care, with the aim
of assessing whether the use of PNs can generate sufficient
income via the MBS to be viable in place of GP-led care.
Because of the variability in charges to patients by GPs and co-
payments across general practices, we restricted our focus to
MBS fees only.
Methods
A cost-analysis of item numbers from the MBS was under-
taken from the perspective of costs to Medicare Australia using
data from participants in a comprehensive study (between
2008 and 2009) that investigated the feasibility, acceptability
and cost-effectiveness of nurse-led management of chronic
disease in a general practice setting.11 A sample of 254 patients
was recruited from three Australian general practices: an urban
(Gold Coast; GC) and regional (Toowoomba; TW) practice in
Queensland, and a rural practice in Victoria. Practices were
purposively selected by employment of a PN, level of com-
puterisation and diversity of geographical and patient popu-
lation. Patients with one or more stable chronic diseases of
type 2 diabetes mellitus (DM), ischaemic heart disease (car-
diovascular disease; CVD) and hypertension (HT) were
recruited from these practices. Patients so classified at an
initial GP assessment were randomly allocated to either PN-
or GP-led (i.e. usual practice) care. Further details of patient
recruitment, randomised allocation of patients to treatment
group and methods of data collection have been reported
previously.11 There were two PNs and one to four GPs
involved at each practice in the study over the 2-year period.
All PNs in the study were registered nurses working within
their scope of practice where the PN, rather than working
under the direct supervision of the GP, worked from protocols
in a collaborative practice model. If patients in the PN-led
care group became unstable, they could be referred back to
GP care until their disease stabilised and then return to PN-
led care.
The frequency of GP and PN visits, MBS item numbers and
clinical and demographic characteristics were captured for each
patient from the electronic records 12 months before entering
the study (pre-intervention) and 12 months after (intervention).
Additional data were obtained by patient questionnaires at
baseline (pre-intervention) and at 2 years, including quality of
life measured using the EuroQol 5-Dimensions (EQ-5D-3L),
scored with the Australian algorithm.12 The EQ-5D-3L mea-
sures health status and assigns valuations for 243 health states.
Full health is scored as 1.0 and dead as 0.0; for severe states of
suffering it is possible to have health states worse than death. All
MBS item numbers weremapped to the November 2009MBS13
and all charges are reported in 2009 Australian dollars. Ethics
approval for the study was obtained from relevant ethics
committees.
Statistical analysis
To test the effect of GP- and PN-led care on total MBS charges
per patient, a log-linear regression model was used with the
inclusion of dummy variables for pre-intervention and for the
GP and/or PN group, as well as accounting for several covari-
ates. The distribution of total MBS charges was highly non-
normal in respect to both skewness and kurtosis, and data were
transformedusing a zero-skewness log transformation.14–17The
Kolmogorov–Smirnov standardised test on the transformed
zero-skewed total MBS item charge indicated normality
(P = 0.85).
Two models are estimated using an ordinary least-squares
(OLS) estimator. The first used the full pooled sample and is
represented by Eqn (1):
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lnðMBS:chargeÞpooled ¼ b0 þ b1:ageþ b2:eq5d
þ b3:DMdummy þ b4:HTdummy þ b5:GoldCoastdummy
þ b6:RuralVicdummy þ b7:PreControldummy
þ b8:PostControldummy þ b9:PostTreatmentdummy þ ei
ð1Þ
where eq5d represents the EQ-5D-3L, DM represents diabetes
mellitus, HT represents hypertension, PreControl and PostCon-
trol define observations from the GP-treated control group before
and after PN intervention, PostTreatment define observations
from the PN-treated group after intervention and location
controls of Gold Coast and Rural Victoria.
Model 2 comprises a series of related functions that are
estimated for each chronic condition (Models 2a–c). The func-
tions take the same form as Eqn (1) with the removal of the
DM and HT dummy variables.
The OLS estimator is robust following the transformation
of the dependent variable. Testing for possible multicolliniarity
between independent variables using the variance inflation factor
(v.i.f.) produced nonsignificant results (mean v.i.f. ranging be-
tween 1.22 and 1.37). The Ramsey RESET procedure testing for
omitted variables also produced non-significant results ranging
between P= 0.295 and P= 0.446
Coefficients of the above functions, once the exponential is
taken, give the percentage change in MBS charge (Y) for a 1 unit
change in each independent variable.18 In addition, coefficients
are retransformed to provide mean dollar values to assess the
treatment effect using the smearing method.19 All analyses were
performed using STATA version 12.20
Results
The sample comprised 20% recruited from the GC, 48% from
TW and 32% from Victoria (Table 1). One-third of patients in
TW were in each chronic disease group. In GC and Victorian
practices, 62% and 42% of patients had DM, respectively, with
the remaining patients evenly divided betweenCVDandHT.The
random allocation of patients into the intervention group (those
treated under PN managed care) and control (GP managed care)
was stratified by geographic location. Over the course of the
study, three patients died (two in GP-led care and one in PN-led
care). No patients in the PN-led care requested reassignment to
GP-led care, but four patients were reassigned to the GP due to
deterioration of their condition. The average age was 66.7 years
(range 34–90 years) and 31% had an established diagnosis of
DM, 28% had CVD and 42% had HT. The EQ-5D scores
ranged from 0.23 to 1.0, with an average of 0.81. The baseline
sample suggests successful randomisation.
The number of total visits per patient more than doubled
from before to during the intervention period for all three
chronic diseases (Table 2). The mean number of visits and total
MBS charges per patient also increased over the same period.
For those in the GP-led group, total visits (per patient) increased
from before to during the intervention period by 123% for
DM (mean visits 5.7 vs 12.9, respectively), by 148% for CVD
(mean visits 5.7 vs 14.2, respectively) and by 134% forHT (mean
visits 5.7 vs 13.4, respectively). Similarly, for patients in the
PN-led care group, total visits to the practice increased from
before to during the intervention period by 301% for DM (mean
visits 5.78 to 23.17, respectively), by 250% for CVD (mean visits
5.73 to 20.03, respectively) and by 190%forHT (mean visits 5.73
to 16.59, respectively).
For the 12-month intervention period, participants with CVD
in the PN-led care group had a greater number of GP visits
compared with patients in the GP group (15.06 v. 11.00,
respectively; P = 0.011, t-test). Patients with DM and HT had
similar numbers of GP visits for the GP-led and PN-led care
groups (P= 0.262 and P= 0.342, respectively; t-test). A compar-
ison of the number of visits to PNs across both treatment groups
Table 1. Baseline characteristics of trial participants
Unless indicated otherwise, data show the number of patients in each group,
with percentages in parentheses. PN, practice nurse; GP, general practitioner;
EQ-5D, EuroQol-5 dimensions; DM, type 2 diabetes mellitus; CVD,





Mean (± s.d.) age (years) 68.52 ± 10.84 66.16 ± 9.89
Female 59 (49%) 72 (53%)
Mean (± s.d.) EQ-5D score 0.81 ± 0.18 0.81 ± 0.15
DM 35 (29%) 43 (32%)
CVD 31 (26%) 39 (29%)
HT 54 (45%) 52 (39%)
Urban (GC)A 23 (19%) 27 (20%)
Regional (TW)B 57 (48%) 66 (49%)
Rural (Vic.)C 40 (33%) 42 (31%)
AFor the GC practice, 14.0%, 24.0% and 62.0% of patients had DM, CVD
or HT, respectively.
BFor the TW practice, 39.0%, 28.5% and 32.5% of patients had DM, CVD
or HT, respectively.
CForVictorian practice, 28.9%, 28.9%and42.2%of patients hadDM,CVD
or HT, respectively.
Table 2. Mean visits and total Medicare Benefit Schedule charges before and after the 12-month intervention (with practice nurse- or general
practitioner-led care) according to chronic disease
MBS, Medicare Benefit Schedule; PN, practice nurse; GP, general practitioner



















GP visits (n) 5.78 11.28 9.89 5.71 11.00 15.06 4.21 10.31 11.80
PN visits (n) 0.00 1.63 13.29 0.01 3.23 4.97 0.01 3.12 4.80
Total no. visits 5.78 12.91 23.17 5.73 14.23 20.03 5.73 13.42 16.59
Total MBS (A$, 2009) 361.41 641.44 953.99 380.04 724.61 1057.88 380.04 732.32 713.80
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revealed that CVD patients in the PN-led care group made more
PN than GP visits (4.97 vs 3.23, respectively; P= 0.013), DM
patients in the PN-led care group had considerably more PN
visits (13.29 vs 1.63, respectively; P < 0.001) and HT patients
in the PN-led care group had marginally more PN visits (4.80 vs
3.12, respectively; P = 0.013).
All GP and PN visits, and their associated MBS item costs,
are included in the revenue analysis. This includes visits directly
associated with patients’ chronic conditions and those not.
During the intervention period, half of all visits were attributed
as being directly related to the management of patients’ chronic
conditions. Over the 12-month intervention period, patients on
average made approximately five visits to a GP for the purposes
of managing their stable chronic condition. This figure corre-
sponds well with GP consultation data from the Australian
HealthSurvey, 2011–12 for each chronic condition.21 In addition,
MBS data show that for the general population there were
claims for 6.5 professional services per person in 2008–09,
including specialists visits.22
A range of MBS item codes for GP ‘Professional
Attendances’ are the clear drivers of the MBS costs measured
in the present study. Over 45% of all MBS item numbers
claimed are associated with the MBS Group A–Professional
Attendances (Table 3). These GP attendances claim amounts
range from A$27.73 to A$253.30. The most common item
number claimed was A1–23 for a 20-min consultation. In
contrast, the item numbers associated with PN attendances
(M2) and loadings for regional and rural medical practices
(M1) also account for approximately 45% of the total number
of claim items, but these item amounts ranged only between
A$6.65 and A$11.35. The remaining 10% of item numbers
claimed were spread across Diagnostic Imaging, Therapeutic
and Pathology. The claims associated with medicine scripts
were not included in the analysis.
The costs (total annual item charges) relative to the pre-
intervention period using pooled data for all three chronic dis-
eases had positive and significant coefficients for the GP- and
PN-led care groups for the intervention period (P < 0.001;
Table 4), indicating higher costs during the intervention period.
The variables age, EQ-5D, DM, and Victoria (rural) were also
significant (P < 0.001). Of these, the EQ-5D score (as measured
at the pre-intervention period) was inversely associated with
MBS item charges. On average, a 1% increase in the EQ-5D
score resulted in a 44.5% (exp–0.60 = 0.5548) decrease in MBS
item charges. Relative to patients with CVD, DM and HT
patients had 17% higher had 15% lower MBS total item
charges, respectively. Controlling for location, the Victorian
group had higher mean MBS item charges of 21% relative to
regional (TW) study participants. In addition, for each year
increase in age, mean MBS item charges increased by 2%.
The same regression analysis was repeated for each of the
three chronic diseases (Table 4). These tables show differing
results with respect to geographic location and allocation to PN-
or GP-led care groups. For each of the three diseases, variables
from both the PN- and GP-led care groups are positive and
highly significant, indicating greater numbers of visits to PNs
and GPs. Relative to TW study participants, those with DM in
the urban (GC) practice had greater total MBS charges, as did
those with CVD and HT patients in Victoria.
The GP group recorded re-transformed charge increases of
A$396 above the pre-intervention phase (Table 5), whereas the
corresponding increase in total MBS item charges for the PN-led
care group was A$524. This re-transformation is based on
Model 1. Thus, the net additional cost of PN-led care over GP-
led care was A$129 per participant per year.
Discussion
The present study compared total MBS charges for patients
who were managed for their stable chronic disease by either
usual GP- or PN-led care. Our main findings showed that total
MBS claims increased by a mean of A$129 per patient for
PN-led care above GP-led care over a 1-year period, having
controlled for age, self-reported quality of life and geographic
location of practice. Patients with CVD recorded the highest
number of GP and second highest number of PN visits in the
intervention period. Patients with DM recorded the highest
mean number of PN visits and a large increase in the number
of GP visits during the intervention period. As a result, CVD
and DM patient groups had higher mean MBS charges (total
annual costs) relative to HT patients. The combined additional
consultations with GPs and PNs drive the majority of these
increases.
The notion that a PN-led model of care would free up GPs to
attend to more acute problems and thereby improve healthcare
delivery cost-effectively was not supported. GPs were busier
with their trial patients, perhaps due a Hawthorne effect,23 or
because of the natural deterioration of the chronic diseases as
patients aged. Similarly, PNs were significantly busier, perhaps
for the same reasons, or because of the time demands of
individual care plans, the assumption of a new role and the
need to refer patients becoming unstable or developing a new
Table 3. Number of charges recorded and mean costs, by Medical Benefits Schedule groups and item numbers
Medicare Benefit Schedule (MBS) group are as follows: A, professional attendances (A1, general practitioner (GP) attendance to which no other items apply;
A15, GP management plans, team care arrangements, multidisciplinary care plans); M, miscellaneous services (M1, additional bulk billing for general
medical services; M2, services provided by a practice nurse (PN) on behalf of a medical practitioner); D, diagnostic imaging services; T, therapeutic procedures;
P, pathology; Script, provision of a script
MBS group (item numbers)










D T P Script
Number (%) 1690 (29%) 264 (5%) 403 (7%) 325 (6%) 2237 (38%) 444 (8%) 121 (2%) 142 (2%) 11 (0.2%) 263 (5%)
Mean (± s.d.) cost
for item (A$)
34 ± 0 67.7 ± 20.7 88.0 ± 30.6 97.9 ± 61.2 8.4 ± 2.4 11 ± 0 36.4 ± 21.3 129.4 ± 92.6 7.3 ± 3.9 N/A
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problem. Furthermore, some extra GP visits could have been
offset by PNs preventing or detecting problems early, but the
data cannot analyse these effects. The analysis presented here
focused on the overall (average) difference in total charges
(revenue from MBS) between PN- and GP-led care rather than
delving into individual patient care pathways and complications.
Table 4. Ordinary least-squares regression analysis of zero-skewed log-transformed Medicare Benefit Schedule (MBS)
item charges (A$, 2009)
EQ-5D,EuroQol-5dimensions;DM, type2 diabetesmellitus;CVD, cardiovascular disease;HT, hypertension; PN, practice nurse;
GP, general practitioner; CI, confidence interval
Variables Coefficient P-value 95% CI
Lower Upper
Model 1: pooled data
Constant 4.70 <0.001 4.20 5.21
Age 0.02 <0.001 0.02 0.03
EQ-5D –0.60 <0.001 –0.92 –0.27
Chronic condition: base CVD
DM 0.17 0.022 0.02 0.32
HT –0.15 0.032 –0.29 –0.01
Location: base regional (Toowoomba)
Gold Coast 0.08 0.265 –0.06 0.23
Rural (Victoria) 0.21 0.001 0.09 0.34
Intervention: base pre-intervention (treatment)
Pre-intervention (control) –0.01 0.893 –0.16 0.14
PN care 0.81 <0.001 0.66 0.96
GP care 0.71 <0.001 0.56 0.85
Adjusted R2 0.390
Model 2a: DM model
Constant 4.93 <0.001 4.19 5.68
Age 0.02 <0.001 0.01 0.03
EQ-5D –0.57 0.033 –1.09 –0.05
Location: base regional (Toowoomba)
Gold Coast 0.38 0.018 0.07 0.69
Rural (Victoria) 0.07 0.492 –0.13 0.26
Intervention: base pre-intervention (treatment)
Pre-intervention –0.04 0.731 –0.29 0.20
PN care 0.71 <0.001 0.46 0.96
GP care 0.41 0.001 0.18 0.64
Adjusted R2 0.356
Model 2b: CVD model
Constant 3.90 <0.001 2.87 4.93
Age 0.03 <0.001 0.02 0.04
EQ-5D –0.41 0.125 –0.94 0.12
Location: base regional (Toowoomba)
Gold Coast 0.01 0.933 –0.26 0.29
Rural (Victoria) 0.22 0.047 0.00 0.44
Intervention: base pre-intervention (treatment)
Pre-intervention –0.02 0.909 –0.30 0.26
PN care 0.84 <0.001 0.56 1.12
GP care 0.63 <0.001 0.37 0.89
Adjusted R2 0.403
Model 2c: HT model
Constant 4.74 <0.001 3.95 5.53
Age 0.02 <0.001 0.01 0.03
EQ-5D –0.65 0.044 –1.28 –0.02
Location: base regional (Toowoomba)
Gold Coast 0.07 0.525 –0.15 0.30
Rural (Victoria) 0.30 0.006 0.09 0.52
Intervention: base pre-intervention (treatment)
Pre-intervention 0.04 0.740 –0.21 0.29
PN care 0.88 <0.001 0.63 1.13
GP care 1.00 <0.001 0.75 1.26
Adjusted R2 0.386
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Of note was that the mix of GP and PN visits varied markedly
between chronic diseases, suggesting different care loads.
Nevertheless, each chronic disease patient who was managed
by a PN generated additional MBS income for the practice due
to more frequent contact with the practice. The mean increase
in total MBS charges was A$129 per annum (approximately
A$140 in 2013 values) for PN-led care over GP-led care. For
a practice to employ a PN without incurring additional costs to
the practice, some additional calculations are required to identify
the break-even point, as now described. The cost to employ a
PN in a general practice comprises the national average hourly
wage rate for a registered nurse working in a general practice
(approximately A$33 in 2013), plus salary on-costs of 25%,
plus an additional 25% for workplace overheads. This sums to
approximately A$52 per hour to employ a PN.
The new PNIP introduced in July 2012 requires a registered
general nurse to work a minimum of 12 h 40min per week for an
annual payment to the practice of A$25 000.4 This is approxi-
mately A$38 per hour. Additional loadings are available for
inner regional to very remote practices and for Department of
Veteran’s Affairs clients. At the time the present study was
undertaken, various claims needed to be made for each PN
item. We had previously calculated that for a general practice
to break even from employing a PN, the PN will need to spend
no more than an average of 2.7 h on each patient per year
(including non-patient contact time) and a full-time PN
(37.25 h per week) should manage at least 717 chronic disease
patients. The new PNIP incorporates all PN MBS items into a
single payment, which should reduce administrative burden
and improve efficiency. However, the margin for salary on-costs
and workplace overheads means that greater income will need
to be generated by the practice to cover any shortfalls.
There exists an obvious expenditure implication for the
Australian Government by promoting the role of PNs as a
means of increasing the capacity of the primary health care
sector and attempting better management of long-term chronic
conditions (i.e. more PNs means more expenditure on PNs).
However, this increase in expenditure for chronic conditions
may lead to total health care expenditure savings in the future
by limiting the number and duration of chronic disease
hospital admissions.24,25 Recent evidence is mixed. With CVD
alone having a health expenditure of A$1.8 billion dollars
in 2004–05, and approximately 72 per cent of this coming
from in-patient hospital costs,26 attempts to promote more
primary health care chronic disease management may provide
the Australian Government with savings in total health
expenditure.
The limitations of the study include the small sample sizes for
each chronic disease across PN and GP groups and three sample
locations, which potentially reduce some generalisability of the
study’s conclusions. However, the diversity of geographical
locations is an overall strength, despite the confounding between
geographic location and practice behaviour. The three chronic
diseases selected are frequently seen in general practice and
therefore the results and subsequent calculations provide a good
guide to the cost and expected workload of a GP employing
PNs. We know nothing about the maintenance of the effect long
term. We have evaluated MBS costs and not total costs (i.e. we
did not evaluate the total fees charged by the practice). Fees
charged by the practice will be subject to wide variation depend-
ing on locality and the population the practice services. It is
apparent that patients will access services (or MBS items) more
frequently under this PN-led model of care and potentially
increase total costs to the MBS; whether the additional costs
lead to better health outcomes (improved quality of life,
reduced admissions to hospital, longer survival) remains un-
known. A much larger trial that includes these end-points is
needed to address these questions. An additional weakness of
the study is the possible artefact of the pre-intervention data
(e.g. patient records may be truncated for new patients and/or
patient records for the pre-intervention period are more likely to
have been incomplete because the main focus was on the inter-
vention period). However, these factors will have had similar
effects on both the PN and GP groups.
Conclusion
Medicare reimbursements provide sufficient funding for general
practices to employ PNs within limits of workloads.
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